BD Medical has signed an agreement with Medtronic to launch a new insulin pump infusion set with BD FlowSmart technology.
Under the agreement, BD will manufacture the product, while Medtronic will commercialise the infusion set, which delivers insulin from the pump to the body and forms a critical part of the overall system.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Medtronic Diabetes Service and Solutions vice-president Annette Bruls said: "Medtronic is committed to advancing innovation across the entire insulin pump system, including infusion sets, to improve outcomes and expand options to satisfy different patient needs, body types and lifestyles."
BD Medical-Diabetes Care worldwide president Kenneth Miller said: "By increasing the reach and availability of this technology, we have an opportunity to enhance the use of insulin pump therapy by providing potentially more consistent insulin delivery and fewer flow interruptions."
The BD FlowSmart technology-equipped insulin infusion set features a side-ported catheter that will improve insulin flow, potentially lowering the number of flow interruptions, which is defined as a continuous rise in inline pressure lasting at least half an hour.
Additional components include the smallest insertion needle currently available, measuring 30 gauge, which is designed to reduce insertion pain.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDeveloped in collaboration with JDRF and the Leona M and Harry B Helmsley Charitable Trust to improve the treatment of type 1 diabetes, the infusion set is designed to work with both Medtronic insulin pumps and other manufacturers’ insulin pumps.
Having secured both US Food and Drug Administration clearance and Health Canada approval in April and January 2015, the infusion set is expected to be launched in 2016.
An application has also been submitted for CE marking.
According to pre-clinical and clinical data presented at American Diabetes Association’s 75th Scientific Sessions, the set significantly lowered flow interruptions, including silent occlusions, compared to other commonly used infusion sets during three different studies.
